Home Cart Sign in  
Chemical Structure| 1369489-71-3 Chemical Structure| 1369489-71-3

Structure of Palupiprant
CAS No.: 1369489-71-3

Chemical Structure| 1369489-71-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

E7046 is a specific antagonist of the type 4 prostaglandin E2 (PGE2) receptor EP4. It possesses significant antitumor growth activity in multiple preclinical tumor models through modulating myeloid cells, including tumor-associated macrophages and myeloid-derived suppressor cells.

Synonyms: E-7046; ER-886406; Palupiprantum

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Palupiprant

CAS No. :1369489-71-3
Formula : C22H18F5N3O4
M.W : 483.39
SMILES Code : O=C(C1C=CC([C@H](C)NC(=O)C2C(C(F)F)=NN(C)C=2OC2C=C(C(F)(F)F)C=CC=2)=CC=1)O
Synonyms :
E-7046; ER-886406; Palupiprantum
MDL No. :MFCD30502665
InChI Key :MKLKAQMPKHNQPR-NSHDSACASA-N
Pubchem ID :56944705

Safety of Palupiprant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Palupiprant

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human monocytes 10, 100, 300, 1000, 3000 nM 7 days To evaluate the inhibitory effect of E7046 on PGE2-mediated monocyte differentiation toward M2-like macrophages. Results showed that E7046 dose-dependently reversed PGE2-induced differentiation toward CD1a-CD16+ macrophages, promoted differentiation toward CD1a+CD16- dendritic cells, and reduced the expression of M2-like phenotype markers CD163 and CD206. Oncoimmunology. 2017 Jun 28;6(8):e1338239
Mouse bone marrow cells 1 µM 8 days To evaluate the inhibitory effect of E7046 on PGE2-mediated suppression of mouse bone marrow cell differentiation toward dendritic cells. Results showed that E7046 dose-dependently reversed PGE2-induced suppression of CD11c+ dendritic cell differentiation and restored T cell proliferation capacity. Oncoimmunology. 2017 Jun 28;6(8):e1338239

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice CT26 colon cancer model Oral 150 mg/kg Once daily for 21 days To evaluate the anti-tumor activity of E7046 in vivo and its immunomodulatory mechanisms. Results showed that E7046 significantly inhibited tumor growth in multiple mouse tumor models including CT26 colon cancer and 4T1 breast cancer, and this effect was dependent on CD8+ T cells and myeloid cells. Immunophenotyping revealed that E7046 reduced the proportion of immunosuppressive MDSCs and M2-like macrophages in tumors while increasing M1-like macrophages and tumor-infiltrating T cells. Oncoimmunology. 2017 Jun 28;6(8):e1338239
C57BL/6 mice NAFLD murine model Oral 150 mg/kg Every other day for 2 weeks E7046 significantly inhibited M2 macrophage-mediated HSC autophagy and improved liver fibrosis and histopathology in NAFLD mice Cell Mol Life Sci. 2022 May 19;79(6):303
BALB/c mice CT-26 colon cancer xenograft model Oral 150 mg/kg Once daily for 11 days The inhibitory effect of E7046 was demonstrated in CT-26 colon cancer animal models. ACS Med Chem Lett. 2023 May 22;14(6):727-736

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03152370 Neoadjuvant Therapy in Rectal ... More >>Cancer Less << Phase 1 Recruiting January 2019 United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 United States, New York Weill Cornell Recruiting New York, New York, United States, 10065 Poland Marie-Skodowska Curie Cancer Centre Recruiting Warsaw, Poland United Kingdom The Christie Recruiting Manchester, United Kingdom Mount Vernon Hospital Recruiting Northwood, United Kingdom Less <<
NCT02540291 Tumors Phase 1 Terminated(Terminated due to, ... More >>licensing agreement granting exclusive rights of research, development, manufacture and marketing of Eisai's E7046 to Adlai Nortye Biopharma.) Less << - United States, Massachusetts ... More >> Boston, Massachusetts, United States United States, Texas Houston, Texas, United States France Villejuif, Cedex, France Less <<
NCT05358691 Lung Cancer Stage III PHASE1 NOT_YET_RECRUITING 2028-06-01 Emory University, Atlanta, Geo... More >>rgia, 30322, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States Less <<
NCT05191667 Esophageal Cancer PHASE1 SUSPENDED 2025-12-25 Jianming Xu, Beijing, Beijing,... More >> 100853, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.07mL

0.41mL

0.21mL

10.34mL

2.07mL

1.03mL

20.69mL

4.14mL

2.07mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories